In this study, we started a survey about the use of TCIMs by cancer patients with the aim of (i) assessing the use of these products in relation to disease stage and suggested therapies and (ii) analyzing how BP or MBP were chosen in relation to cancer therapies, to highlight the potential risks from harmful combinations. This evidence concerns the gene MBP and cancer.